FRI0342 DOES UNDERSTANDING SLE MATTER TO DISEASE ACTIVITY IN SLE PATIENTS?

A.S. Meara¹, P. Hackenberger², J. Yedimenko³, C. Rodman⁴, S.P. Ardois⁵, E. Peters⁶. ¹Division of Immunology and Rheumatology; ²College of Medicine; ³Internal Medicine, The Ohio State University; ⁴The; ⁵Department of Medicine; ⁶Department of Psychology, The Ohio State University, Columbus, USA

Background: Systemic lupus erythematosus (SLE) is a heterogeneous disease with high morbidity and mortality with complex long-term treatments. These dynamic treatments can be daunting especially to the 25%–60% of SLE patients who have cognitive and neuropsychiatric deficits. Patients lacking understanding of their own baseline health status and treatment options cannot effectively collaborate in making informed choices with their physicians.

Objectives: This project aimed to identify SLE patients' comprehension of their medication regimens and disease outcomes in relation to standard markers of disease activity (SLEDAI) and damage (SLICC DI).

Methods: Patients >18 years were recruited from The Ohio State University (OSU) Lupus Vasculitis Glomerulonephritis (LVG) clinic. An IRB-approved 25-item true/false disease questionnaire was administered to 75 SLE patients who provided informed consent. Individual question and composite scores for each patient were correlated with their SLEDAI and SLICC DI scores. To our knowledge, a disease comprehension questionnaire has never been used in lupus patients.

Results: 75 SLE patients completed the comprehension questionnaire. Lower comprehension was associated with greater disease activity ($r = -0.14$), while no correlation was found between composite score and disease damage (SLICC DI) ($r = -0.03$). Figures 1 plot the comprehension composite scores against the SLEDAI. P values were not significant, but trending to correlate with the r . Evaluation of individual questionnaire items demonstrated: approximately 80% of patients did not associate heart disease with lupus, over 25% of patients did not recognise the side effects of prednisone, and over 15% of patients did not know lupus affects bone health.

Conclusions: These preliminary results suggest that patients with more understanding of their SLE diagnosis, comorbidities, and treatments had less measured disease activity. The comprehension questionnaire and SLEDAI characterise patients in their present disease state, so this correlation likely reflects the evolution of patient understanding and the fluctuating nature of their disease. Alternatively, higher disease activity scores represent more severe disease, which could be associated with greater neurocognitive deficits leading to poorer scores on the comprehension questionnaire. The lack of correlation between composite score and SLICC DI is likely attributed to the discrepancy between a metric evaluating current knowledge and a long-term indicator that may derive from decisions made when patients' comprehension was different than current. These initial results are promising and may represent a cost-effective opportunity for physicians to evaluate and address their patients' comprehension gaps in an effort to improve shared decision making. However, more data are needed to test the robustness of these trends.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5737

FRI0343 BLOOD CONCENTRATIONS OF COMPLEMENT SPLIT PRODUCT IC3B AND SERUM C3 ASSOCIATE WITH SLE DISEASE ACTIVITY

A.H. Kim¹, V. Strand², D. Sen¹, Q. Fu³, N. Mathis¹, M. Schmidt⁴, R. Bruchas⁴, N. Staten⁴, P. Olson⁴, C. Stiening⁴, J. Atkinson¹. ¹Rheumatology, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, Saint Louis; ²Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto; ³Epidemiology and Biostatistics, Saint Louis University; ⁴Kypha, Inc., Saint Louis, USA

Background: The complement system plays a central role in systemic lupus erythematosus (SLE). Since complement activation occurs during SLE flares, complement proteins are predicted to be consumed with concomitant generation of activation-derived products at a rate proportional to the degree of disease activity. However, interpretation of values may be confounded due to the unknown impact of increased acute phase production of C3 and C4, as well as in individuals with low C4 gene copy number who have persistently low serum C4.

Improved detection of complement activation would enhance clinicians' ability to more readily assess SLE disease activity and promptly identify and treat flares. We hypothesise that complement split products are more sensitive measures of complement activation and better correlate with SLE disease activity.

Objectives: To examine correlations between blood levels of complement split product iC3b and serum component C3 with clinically meaningful changes in disease activity in patients with SLE.

Methods: 159 consecutive subjects with American College of Rheumatology or Systemic Lupus International Collaborating Clinics classified SLE were enrolled into CASTLE (Complement Activation Signatures in Systemic Lupus Erythematosus), a prospective observational study. Patients with 1–7 study visits were included in this longitudinal analysis. 48 healthy volunteers were enrolled to establish the normal reference range of iC3b/C3. Serum C3 and C4 were measured by nephelometry. Blood levels of iC3b were assessed by a lateral flow assay. SLE disease activity was monitored utilising the Systemic Lupus Erythematosus Disease Activity Index 2K Responder Index-50 instrument.

Results: iC3b/C3 ratio, double-stranded (ds)DNA antibodies (Abs), and supraphysiologic prednisone dose (>7.5 mg/day) each independently correlated with SLE disease activity employing multilevel multiple logistic regression analysis. Only iC3b/C3 was significantly associated with clinically meaningful improvements in disease activity among subjects receiving supraphysiologic doses of prednisone (high disease activity). iC3b/C3 outperformed C3 and C4 levels in discriminating both active versus inactive SLE disease and major flares versus no disease activity (figure 1). Finally, iC3b/C3, dsDNA Abs, ESR, and supraphysiologic prednisone dose were independently associated with lupus nephritis, while none were associated with SLE rash.

Abstract FRI0343 – Figure 1. ROC curves of iC3b/C3, iC3b, C3, C4, and dsDNA levels distinguishing new major flares from subjects with no SLE activity

Conclusions: Blood iC3b/C3 ratio correlates with SLE disease activity and clinically meaningful improvement in disease activity. Furthermore, it discriminates between active versus inactive SLE, and major flares compared to those patients without disease activity.

Acknowledgements: This research was funded/supported by Kypha, Inc. and National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under Award Number R21AR069833. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Disclosure of Interest: A. Kim Grant/research support from: Kypha, Inc., Consultant for: Exagen Diagnostics, Inc., Speakers bureau: Exagen Diagnostics, Inc., V. Strand Consultant for: Kypha, Inc., Abbvie, Inc., Amgen, Inc., AstraZeneca plc, Bristol Myers Squibb, Celgene Corporation, EMD Serono, Inc., Genentech/Roche Holding AG, GlaxoSmithKline plc, Janssen Pharmaceutica, Eli Lilly and Company, Novartis International AG, Pfizer, Inc. and Union Chimique Belge (UCB), D. Sen: None declared, Q. Fu Consultant for: Kypha, Inc., N. Mathis Consultant for: Kypha, Inc., M. Schmidt Employee of: Kypha, Inc., R. Bruchas Employee of: Kypha, Inc., N. Staten Employee of: Kypha, Inc., P. Olson Employee of: Kypha,

Inc., C. Stiening Employee of: Kypha, Inc., J. Atkinson Consultant for: Kypha, Inc., Compliment Corporation, Gemini Therapeutics, Inc., Celldex Therapeutics, Clinical Pharmacy Services, CDMI, Omeros Corporation, Achillion Pharmaceuticals, Inc., True North Therapeutics, BioMarin Pharmaceutical, Inc., Annexon Biosciences, Inc., and AdMiRx, Inc.

DOI: 10.1136/annrheumdis-2018-eular.1843

FRI0344 SERUM FREE LIGHT CHAINS AS A FLARE BIOMARKER IN SYSTEMIC LUPUS ERYTHEMATOSUS

A.B. Rodriguez Cambon¹, J. Jimenez Jimenez², M.A. Blazquez Cañamero³, M. J. García De Yébenes⁴, F. Rey Pazos⁵, C. Macía Villa¹, M. Alcaide Villar¹, F. Cabero Del Pozo¹, P. Collado Ramos¹, E. Alvarez Andrés¹, A. Cruz Valenciano¹.

¹Rheumatology; ²Immunology, Hospital Universitario Severo Ochoa;

³Rheumatology, Hospital Universitario Ramón y Cajal; ⁴Musculoskeletal Health Institute (InMus); ⁵Rheumatology, Hospital Universitario Infanta Sofía, Madrid, Spain

Background: Complement levels are already known as biomarkers of flare in systemic lupus erythematosus (SLE); currently the usefulness of free light chains (FLC) in different autoimmune diseases in which the B cell has a relevant pathogenic role, as in the case of SLE, is being investigated.

Objectives: To explore the usefulness of FLC determination as a flare biomarker in patients with SLE and to analyse possible discriminative differences between FLC and complement C3 and C4 levels.

Methods: We performed an uncentric prospective longitudinal study with the following inclusion criteria: age greater than 18 years old and fulfilment of ACR or SLICC criteria for the diagnosis of SLE. Exclusion criteria were non-SLE related haematological disease, severe infection and severe kidney disease (Crea>2 mg/dl) to avoid interferences with FLC clearance. SLE flare definition was based on the SFI index. Receiver operator curves (ROC) and calculation of the area under the curve (AUC) were used to compare the discriminative ability between FLC and C3-C4 levels.

Results: 46 patients were enrolled. For the present communication, only baseline data were analysed. 41 (91%) patients were women. Most frequent clinical manifestations were haematological (83%) and cutaneous (72%). Laboratory findings were 98% positive ANA, 67% positive antiDNAc, 54% decreased C3% and 39% decreased C4. 6 (13%) patients presented a SLE flare and their characteristics compared to non-flare patients were lower C3 levels (70 vs 95; p=0,017) and C4 levels (10 vs 17; p=0,008) with higher concentrations of lambda light chains (λ LC) (27 vs 19; p=0,028). In addition, flare patients had higher IgA levels (402 vs 250; p=0,029), higher score in the global assessment of the doctor (4.3 vs 1.6; p=0,0003), longer time disease evolution (17.8 vs 14.3 years; p=0,844), higher values of SLEDAI (2.7±2 vs 1.4±1.3; p=0,083) and higher lymphopenia (982 vs 1474; p=0,068). We found no association between FLC levels and the presence of antiDNAc. The correlation of FLC with the rest of activity biomarkers (C3, C4, SLEDAI, VAS) occurred in the expected way although the magnitude of the association was moderate, with a higher correlation between C3 and λ LC. λ LC were the only FLC that showed ability to discriminate flares (AUC 0.781), with sensitivity 100%, specificity 65% and 69.6% of patients correctly classified for a cut-off point ≥ 19.5 . On the other hand, C3 and C4 also had a high discrimination capacity for flare (AUC 0.804 and 0.837 respectively). Comparing the three parameters, C4 achieved the highest AUC (0.837, 95% CI: 0.663–1000).

Conclusions: Lambda free light chains have a good discrimination capacity for SLE flares and could be useful as a SLE flare biomarker. Longitudinal studies with a larger number of patients are necessary to evaluate its usefulness as a flare predictor.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5374

FRI0345 ASSOCIATION BETWEEN CIGARETTE SMOKING AND SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) – AN UPDATED META-ANALYSIS OF CASE-CONTROL AND COHORT STUDIES

M.H.Y. Chua, I. A. T. Ng, A. Mak. *Medicine, National University of Singapore, Singapore, Singapore*

Background: While the association between cigarette smoking and the occurrence of SLE has been studied over the past two decades, conflicting results have rendered such association controversial. With the global increase in woman smokers and more prospective data addressing the risk of the development of SLE and cigarette smoking being available, it is timely to provide an update on the evidence of the relationship between cigarette smoking and the occurrence of SLE.

Objectives: To study the association between cigarette smoking and the odds, as well as the risk of SLE occurrence by meta-analyses of case-control and cohort studies.

Methods: We performed an extensive literature search using the relevant keywords including "systemic lupus erythematosus"; "lupus"; "smoking"; "cigarette smoking"; "environmental"; "autoimmune disease" and "connective tissue disease" in various combinations to identify case-control and cohort studies addressing the relationship between cigarette smoking and SLE published in English in computerised databases including PubMed (from 1966 to , Jan 2018 Embase (1980 to Jan 2018 and Cochrane Central Register of Control Trials (last quarter of 2017). Effect sizes were pooled as odds ratio (OR) and relative risk (RR) and the corresponding 95% CI for case-control and cohort studies, respectively. Heterogeneity was studied by I^2 . If the effect sizes were associated with low heterogeneity ($I^2 < 40$), the fixed effects model was used. Otherwise ($I^2 \geq 40$), the random effects model was used, based on the model suggested by DerSimonian and Laird.

Results: Thirteen relevant studies (10 retrospective case-control and 3 cohort) were selected for these meta-analyses. Data were aggregated based on smoking statuses comprising current, past, ever and never smoking. Analyses of case-control studies revealed significant relationships between the occurrence of SLE and current smoking (OR 1.639 [1.171–2.295], p=0.004, $I^2=85.8$), and ever smoking (OR 1.438 [1.037–1.995], p=0.029, $I^2=86.3$). However, no significant relationship was found between the occurrence of SLE and past smoking (OR 1.208 [0.853–1.711], p=0.286 $I^2=74.7$). While no relationship was found between the development of SLE and current smoking (RR 1.002 [0.680–1.475], p=0.994, $I^2=51.6$), and ever smoking (RR 1.163 [0.944–1.433], p=0.157, $I^2=0$) when the effect sizes of cohort studies were amalgamated, a significant risk in the development of SLE was found amongst ex-smokers compared with never smokers when the prospective data were combined (RR 1.351 [1.085–1.681], p=0.007, $I^2=28.0$).

Conclusions: Smoking is associated with the occurrence of SLE based on the aggregation of effect sizes from case-control and cohort studies. The higher risk of development of SLE in ex-smokers but not among current and ever smokers compared to never smokers based on prospective data warrants further mechanistic studies to unravel the actual immunologic impact of cigarette smoke on SLE development in different subsets of SLE patients.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6836

FRI0346 NEUTROPENIA IN SYSTEMIC LUPUS: PREVALENCE, SPECIFIC FEATURES AND CLINICAL CONSEQUENCES. RESULTS FROM THE LARGE UPPER RHINE DATABASE LBBR

A. Meyer¹, P.-E. Gavand¹, G. Blaison², T. Martin¹, A.-S. Korganow¹, A. Guffroy¹, on behalf of LBBR Study Group. ¹Clinical Immunology, CHRU Strasbourg, Strasbourg; ²Internal Medicine, CH Colmar, Colmar, France

Background: The prevalence, pathophysiology and underlying causes or consequences of neutropenia in systemic lupus erythematosus (SLE) are still not well defined even if neutropenia seems to be rather common in this disease.¹

Objectives: To evaluate the prevalence of neutropenia in a large cohort of SLE patients and to identify correlation between neutropenia and other socio-demographical, clinical, serological or therapeutic factors.

To precise the influence of chronicity or severity of neutropenia in the course of SLE.

Methods: We used the LBBR database, a cross-sectional collection of detailed socio-demographic, clinical, serological and therapeutic data from 1,078 SLE patients (14 french or german Upper Rhine Hospitals).

Neutropenia was defined by the presence of less than 1800 circulating neutrophils $\times 10^9/L$. Patients with and without neutropenia were compared considering 47 variables.

The second part of the study focused on a subgroup of SLE LBBR patients for which full data were available about the duration and depth of neutropenia. Chronic neutropenia was defined by neutrophils count less than $1,500 \times 10^9/L$ during at least 6 months and moderate and severe neutropenias were defined by neutrophils count less than $1,000 \times 10^9/L$.

Results: Among 1078 SLE patients, 223 (20.7%) were registered with neutropenia during their history. Mean age and sex ratio were comparable to the whole SLE cohort and to patients without neutropenia (mean age: 43.9 years old, sex ratio: 194 F/28 M). In multivariate analysis, neutropenia was associated with lymphopenia (OR=3.44 (2.48–4.80), p=0.0002) and thrombopenia (OR=3.59 (2.55–5.06), p=0.0002). There was no association with susceptibility to infections (OR 0.97 (0.52–1.80), p=0.6640), neither with SLEDAI score, SLE treatments or other ACR criteria.